Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review
BackgroundSquamous cell carcinoma (SCC) is one of the most common subtypes of non-small cell lung cancer, but its treatment options remain limited. Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) have limited efficacy in the treatment of lung SCC. Here, we report an SCC pat...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1188772/full |
| _version_ | 1797685294285193216 |
|---|---|
| author | Zhiqin Zhang Zhiqin Zhang Jiamao Lin Linke Yang Yang Li |
| author_facet | Zhiqin Zhang Zhiqin Zhang Jiamao Lin Linke Yang Yang Li |
| author_sort | Zhiqin Zhang |
| collection | DOAJ |
| description | BackgroundSquamous cell carcinoma (SCC) is one of the most common subtypes of non-small cell lung cancer, but its treatment options remain limited. Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) have limited efficacy in the treatment of lung SCC. Here, we report an SCC patient who developed EGFR-T790M mutation and showed gefitinib resistance achieved an extremely long survival by taking Osimertinib alternatively.Case summaryA patient, 66-year-old non-smoking and drinking male with advanced SCC who was deemed inoperable at the time of diagnosis. The first genetic testing showed deletion mutation of exon 19 of EGFR. The patient was then treated with gefitinib with no significant efficacy. EGFR-T790M mutation was found in the second genetic test. The treatment regimen was changed to radiotherapy with Osimertinib, and the patient’s primary lesion and the brain metastases were well controlled.ConclusionThis typical case highlights the important role of Osimertinib in patients with SCC carrying EGFR mutations. |
| first_indexed | 2024-03-12T00:43:04Z |
| format | Article |
| id | doaj.art-4ab56468788d499099f5c2838a70bb98 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T00:43:04Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-4ab56468788d499099f5c2838a70bb982023-09-15T01:26:18ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-09-011310.3389/fonc.2023.11887721188772Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures reviewZhiqin Zhang0Zhiqin Zhang1Jiamao Lin2Linke Yang3Yang Li4Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Academy of Medical Sciences, Jinan, ChinaDepartment of Traditional Chinese and Western Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University, Academy of Medical Sciences, Jinan, ChinaDepartment of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Academy of Medical Sciences, Jinan, ChinaShandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Academy of Medical Sciences, Jinan, ChinaBackgroundSquamous cell carcinoma (SCC) is one of the most common subtypes of non-small cell lung cancer, but its treatment options remain limited. Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) have limited efficacy in the treatment of lung SCC. Here, we report an SCC patient who developed EGFR-T790M mutation and showed gefitinib resistance achieved an extremely long survival by taking Osimertinib alternatively.Case summaryA patient, 66-year-old non-smoking and drinking male with advanced SCC who was deemed inoperable at the time of diagnosis. The first genetic testing showed deletion mutation of exon 19 of EGFR. The patient was then treated with gefitinib with no significant efficacy. EGFR-T790M mutation was found in the second genetic test. The treatment regimen was changed to radiotherapy with Osimertinib, and the patient’s primary lesion and the brain metastases were well controlled.ConclusionThis typical case highlights the important role of Osimertinib in patients with SCC carrying EGFR mutations.https://www.frontiersin.org/articles/10.3389/fonc.2023.1188772/fullnon-small cell lung carcinomasquamous cell carcinomaEGFR mutationtargeted therapycancer |
| spellingShingle | Zhiqin Zhang Zhiqin Zhang Jiamao Lin Linke Yang Yang Li Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review Frontiers in Oncology non-small cell lung carcinoma squamous cell carcinoma EGFR mutation targeted therapy cancer |
| title | Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review |
| title_full | Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review |
| title_fullStr | Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review |
| title_full_unstemmed | Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review |
| title_short | Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review |
| title_sort | osimertinib inhibits brain metastases and improves long term survival in a patient with advanced squamous cell lung cancer a case report and literatures review |
| topic | non-small cell lung carcinoma squamous cell carcinoma EGFR mutation targeted therapy cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1188772/full |
| work_keys_str_mv | AT zhiqinzhang osimertinibinhibitsbrainmetastasesandimproveslongtermsurvivalinapatientwithadvancedsquamouscelllungcanceracasereportandliteraturesreview AT zhiqinzhang osimertinibinhibitsbrainmetastasesandimproveslongtermsurvivalinapatientwithadvancedsquamouscelllungcanceracasereportandliteraturesreview AT jiamaolin osimertinibinhibitsbrainmetastasesandimproveslongtermsurvivalinapatientwithadvancedsquamouscelllungcanceracasereportandliteraturesreview AT linkeyang osimertinibinhibitsbrainmetastasesandimproveslongtermsurvivalinapatientwithadvancedsquamouscelllungcanceracasereportandliteraturesreview AT yangli osimertinibinhibitsbrainmetastasesandimproveslongtermsurvivalinapatientwithadvancedsquamouscelllungcanceracasereportandliteraturesreview |